International Journal of Nephrology [9] “NKF-DOQI clinical practice guidelines for vascular access. National Kidney Foundation-Dialysis Outcomes Quality Ini- tiative,” The American Journal of Kidney Diseases, vol. 30, pp. S150–S191, 1997. [10] N. S. Hakim, J. Romagnoli, J. C. Contis, J. Akoh, and V. E. Papalois, “Refashioning of an aneurysmatic arterio- venous ﬁstula by using the multiﬁre GIA 60 surgical stapler,” International Surgery, vol. 82, no. 4, pp. 376–377, 1997. [11] J. Gilmore, “KDOQI clinical practice guidelines and clinical practice recommendations—2006 updates,” Nephrology Nurs- ing Journal, vol. 33, no. 5, pp. 487–488, 2006. [12] A. Sultana, F. Torella, R. McWilliams, and A. Bakran, “Axillary artery aneurysm following closure of haemodialysis ﬁstula. A case report,” Journal of Cardiovascular Surgery, vol. 48, no. 2, pp. 197–199, 2007. [13] M. Haimov, A. Baez, M. Neﬀ, and R. Slifkin, “Complications of arteriovenous ﬁstulas for hemodialysis,” Archives of Surgery, vol. 110, no. 6, pp. 708–712, 1975. [14] G. E. Pierce, J. H. Thomas, and J. R. Fenton, “Novel repair of venous aneurysms secondary to arteriovenous dialysis ﬁstulae,” Vascular and Endovascular Surgery, vol. 41, no. 1, pp. 55–60, 2007. [15] G. S. Georgiadis, M. K. Lazarides, S. A. Panagoutsos et al., “Surgical revision of complicated false and true vascular access-related aneurysms,” Journal of Vascular Surgery, vol. 47, no. 6, pp. 1284–1291, 2008. [16] H. M. Burkhart and D. F. Cikrit, “Arteriovenous ﬁstulae for hemodialysis,” Seminars in Vascular Surgery, vol. 10, no. 3, pp. 162–165, 1997. [17] M. L. Mantha, R. Baer, G. S. Bailey, R. L. Wu, and J. P. Killen, “Endovascular repair of a hemodialysis ﬁstula aneurysm with covered stents,” Kidney International, vol. 76, no. 8, p. 918, 2009. [18] T. Lee and P. Roy-Chaudhury, “Advances and new frontiers in the pathophysiology of venous neointimal hyperplasia and dialysis access stenosis,” Advances in Chronic Kidney Disease, vol. 16, no. 5, pp. 329–338, 2009. [19] P. Roy-Chaudhury, B. S. Kelly, M. A. Miller et al., “Venous neointimal hyperplasia in polytetraﬂuoroethylene dialysis grafts,” Kidney International, vol. 59, no. 6, pp. 2325–2334, 2001. [20] R. P. Campos, M. M. Do Nascimento, D. C. Chula, D. E. Do Nascimento, and M. C. Riella, “Stenosis in hemodialysis arteriovenous ﬁstula: evaluation and treatment,” Hemodialysis International, vol. 10, no. 2, pp. 152–161, 2006. [21] P. Goldwasser, M. M. Avram, J. T. Collier, M. A. Michel, S. A. Gusik, and N. Mittman, “Correlates of vascular access occlu- sion in hemodialysis,” American Journal of Kidney Diseases, vol. 24, no. 5, pp. 785–794, 1994. [22] R. A. Bonomo, D. Rice, C. Whalen, D. Linn, E. Eckstein, and D. M. Shlaes, “Risk factors associated with permanent access-site infections in chronic hemodialysis patients,” Infection Control and Hospital Epidemiology, vol. 18, no. 11, pp. 757–761, 1997. [23] I. Saeed Abdulrahman, S. H. Al-Mueilo, H. A. Bokhary, G. Ladipo, and A. Al-Rubaish, “A prospective study of hemodialysis access-related bacterial infections,” Journal of Infection and Chemotherapy, vol. 8, no. 3, pp. 242–246, 2002. [24] K. B. Stevenson, E. L. Hannah, C. A. Lowder et al., “Epi- demiology of hemodialysis vascular access infections from longitudinal infection surveillance data: predicting the impact of NKF-DOQI clinical practice guidelines for vascular access,” American Journal of Kidney Diseases, vol. 39, no. 3, pp. 549– 555, 2002. [25] J. I. Tokars, E. R. Miller, and G. Stein, “New national surveillance system for hemodialysis-associated infections: 5 initial results,” American Journal of Infection Control, vol. 30, no. 5, pp. 288–295, 2002. [26] G. Taylor, D. Gravel, L. Johnston et al., “Prospective surveillance for primary bloodstream infections occurring in Canadian hemodialysis units,” Infection Control and Hospital Epidemiology, vol. 23, no. 12, pp. 716–720, 2002. [27] N. R. Powe, B. Jaar, S. L. Furth, J. Hermann, and W. Briggs, “Septicemia in dialysis patients: incidence, risk factors, and prognosis,” Kidney International, vol. 55, no. 3, pp. 1081–1090, 1999. [28] J. H. Tordoir, J. M. Herman, T. S. Kwan, and P. M. Diderich, “Long-term follow-up of the polytetraﬂuoroethylene (PTFE) prosthesis as an arteriovenous ﬁstula for haemodialysis,” European Journal of Vascular Surgery, vol. 2, no. 1, pp. 3–7, 1988. [29] A. M. Verhallen, M. P. Kooistra, and B. C. van Jaarsveld, “Cannulating in haemodialysis: rope-ladder or buttonhole technique?” Nephrology Dialysis Transplantation, vol. 22, no. 9, pp. 2601–2604, 2007. [30] J. Tordoir, B. Canaud, P. Haage et al., “EBPG on Vascular Access,” Nephrology Dialysis Transplantation, vol. 22, supple- ment 2, pp. ii88–ii117, 2007. [31] M. McCann, H. Einarsd o´ttir, J. P. Van Waeleghem, F. Mur- phy, and J. Sedgewick, “Vascular access management 1: an overview,” Journal of Renal Care, vol. 34, no. 2, pp. 77–84, 2008. [32] G. Di Minno, J. Martinez, M. L. McKean, J. De La Rosa, J. F. Burke, and S. Murphy, “Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis,” American Journal of Medicine, vol. 79, no. 5, pp. 552–559, 1985. [33] G. Eknoyan and C. H. Brown III, “Biochemical abnormalities of platelets in renal failure. Evidence for decreased platelet serotonin, adenosine diphosphate and Mg-dependent adeno- sine triphosphatase,” American Journal of Nephrology, vol. 1, no. 1, pp. 17–23, 1981. [34] G. Eknoyan, S. J. Wacksman, H. I. Glueck, and J. J. Will, “Platelet function in renal failure,” New England Journal of Medicine, vol. 280, no. 13, pp. 677–681, 1969. [35] G. Remuzzi and F. Pusineri, “Coagulation defects in uremia,” Kidney International, vol. 24, pp. S13–S17, 1988. [36] V. T. Turitto and H. J. Weiss, “Red blood cells: their dual role in thrombus formation,” Science, vol. 207, no. 4430, pp. 541–543, 1980. [37] D. T. Domoto, J. E. Bauman, and J. H. Joist, “Combined aspirin and sulﬁnpyrazone in the prevention of recur- rent hemodialysis vascular access thrombosis,” Thrombosis Research, vol. 62, no. 6, pp. 737–743, 1991. [38] R. Sreedhara, J. Himmelfarb, J. M. Lazarus, and R. M. Hakim, “Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study,” Kidney International, vol. 45, no. 5, pp. 1477–1483, 1994. [39] J. S. Kaufman, T. Z. O’Connor, J. H. Zhang et al., “Random- ized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis,” Journal of the American Society of Nephrology, vol. 14, no. 9, pp. 2313–2321, 2003. [40] M. A. Crowther, C. M. Clase, P. J. Margetts et al., “Low- intensity warfarin is ineﬀective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial,” Journal of the American Society of Nephrology, vol. 13, no. 9, pp. 2331–2337, 2002. [41] M. Israel, “Depression in dialysis patients: a review of psychological factors,” Canadian Journal of Psychiatry, vol. 31, no. 5, pp. 445–451, 1986.